Tirzepatide vs Mounjaro: Are They the Same Drug?
Tirzepatide is the generic name; Mounjaro and Zepbound are brand names. Understand the differences in approval, dose, cost, and when compounded tirzepatide makes sense.
More on GLP-1 Treatment Comparisons
Ozempic vs Mounjaro: Which Is Right for You?
Head-to-head comparison of semaglutide and tirzepatide by outcome.
Zepbound vs Mounjaro: Same Drug, Different Labels
Why two brand names exist for the same tirzepatide molecule.
Tirzepatide vs Semaglutide 2026
Updated 2026 clinical comparison of both GLP-1 classes.
Compounded Tirzepatide Cost Guide
How much compounded tirzepatide costs and what affects pricing.
The Short Answer: One Drug, Multiple Names
If you have been researching GLP-1 weight loss medications, you have almost certainly encountered the names tirzepatide, Mounjaro, and Zepbound used interchangeably — and wondered whether they are actually the same thing. The simple answer: tirzepatide is the active pharmaceutical ingredient (the drug molecule itself), while Mounjaro and Zepbound are brand names under which Eli Lilly manufactures and sells tirzepatide for specific FDA-approved uses.
Think of it like ibuprofen, Advil, and Motrin. Ibuprofen is the generic molecule. Advil and Motrin are branded versions of the same compound sold under different names. The molecule is chemically identical; the difference lies in who makes it, what it is approved for, and how it is marketed.
Quick Reference: Tirzepatide Names
- Tirzepatide: The generic/active ingredient name — the actual drug molecule
- Mounjaro: Eli Lilly brand name — FDA-approved for type 2 diabetes (May 2022)
- Zepbound: Eli Lilly brand name — FDA-approved for chronic weight management (November 2023)
- Compounded tirzepatide: Same active ingredient, made by licensed compounding pharmacies at lower cost
FDA Approval Differences: Mounjaro vs Zepbound
The distinction between Mounjaro and Zepbound exists entirely because of FDA approval pathways, not because of any difference in the drug itself.
Mounjaro was approved by the FDA in May 2022 for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. The approval was based on the SURPASS clinical trial program, which showed significant HbA1c reductions (up to 2.3 percentage points) and substantial weight loss (15–22% body weight) across all tirzepatide doses.
Zepbound was approved in November 2023 for chronic weight management in adults with BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). The approval was based on the SURMOUNT trial program.
Mounjaro
- FDA-approved for: Type 2 diabetes
- Approved: May 2022
- Insurance coverage: Broader (diabetes benefit)
- Pen color: Teal/green labeling
- Doses available: 2.5–15 mg weekly
Zepbound
- FDA-approved for: Obesity / weight management
- Approved: November 2023
- Insurance coverage: Narrower (obesity benefit)
- Pen color: Distinct Zepbound branding
- Doses available: 2.5–15 mg weekly
Despite these labeling differences, many physicians prescribe Mounjaro off-label for weight loss (before Zepbound was available, and still today if a patient's insurance covers Mounjaro but not Zepbound). Learn how this compares to semaglutide options in our tirzepatide vs semaglutide 2026 comparison.
How Tirzepatide Works: The Dual Mechanism
Tirzepatide is unique among GLP-1 medications because it is a dual agonist — it activates two incretin receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This is why tirzepatide is sometimes called a "twincretin."
By contrast, semaglutide (Ozempic, Wegovy) is a pure GLP-1 agonist. The addition of GIP activity in tirzepatide appears to amplify weight loss and metabolic improvements beyond what GLP-1 agonism alone produces. The SURMOUNT-1 trial showed tirzepatide 15 mg achieved 22.5% mean body weight loss — the highest weight reduction ever recorded in a weight loss drug trial at the time of publication.
Tirzepatide Clinical Outcomes (SURMOUNT / SURPASS Trials)
- Mean weight loss at 15 mg: 20–22.5% body weight over 72 weeks
- HbA1c reduction: Up to 2.3 percentage points in type 2 diabetes
- Fasting glucose: Significant reductions across all doses
- Cardiovascular benefit: SURMOUNT-MMO trial (2024) confirmed CV risk reduction
- Responder rate: 91% achieved ≥5% weight loss at 15 mg
Cost Comparison: Brand vs Compounded Tirzepatide
Cost is one of the most significant practical differences between brand-name Mounjaro/Zepbound and compounded tirzepatide. Here is a realistic comparison:
| Option | Monthly Cost | With Insurance | Notes |
|---|---|---|---|
| Mounjaro (brand) | ~$1,023–$1,069 | $25–$150 (diabetes) | Savings card available |
| Zepbound (brand) | ~$1,059 | Varies widely | Obesity coverage limited |
| Compounded tirzepatide | $125–$345 | Usually not covered | Via licensed compounding pharmacy |
For patients without adequate insurance coverage — which includes the majority of people seeking tirzepatide for weight loss — compounded tirzepatide offers a cost savings of 65–87% compared to the brand-name product. For a full breakdown of compounding costs, see our compounded tirzepatide cost guide.
Compounded Tirzepatide: What It Is and How It Differs
Compounded tirzepatide is produced by state-licensed compounding pharmacies (503A or 503B) that source pharmaceutical-grade tirzepatide and formulate it into injectable preparations. Because tirzepatide remains on the FDA drug shortage list (as of April 2026), compounding pharmacies can legally produce it under the shortage exemption provisions of federal law.
Key things to know about compounded tirzepatide:
- Same active ingredient: Legitimate compounded tirzepatide uses the same tirzepatide base molecule as Mounjaro and Zepbound.
- Requires a prescription: A licensed physician must prescribe compounded tirzepatide — it cannot be legally obtained without one.
- Not FDA-approved as a finished product: The compounded formulation itself has not gone through FDA approval, unlike Mounjaro/Zepbound.
- Quality varies by pharmacy: Always verify your pharmacy is state-licensed, uses USP standards, and provides a Certificate of Analysis for each batch.
See our detailed comparison of Zepbound vs Mounjaro for more on the brand-name side of the equation.
Who Should Use Each Option
Use Mounjaro (brand) if...
- You have type 2 diabetes and your insurance covers Mounjaro
- You have a Mounjaro savings card reducing cost to $25–$150/month
- You want the highest regulatory certainty (FDA-approved finished product)
- Your physician specifically recommends the brand-name formulation
Use Zepbound (brand) if...
- You are seeking tirzepatide for weight management (not diabetes)
- Your insurance has an obesity benefit covering Zepbound
- You want a brand-name product with obesity-specific FDA approval
- Cost is manageable with insurance or Lilly's savings program
Use compounded tirzepatide if...
- You do not have insurance coverage for Mounjaro or Zepbound
- Brand-name cost ($1,000+/month) is not sustainable for you
- You are working with a telehealth provider that uses a licensed compounding pharmacy
- You have confirmed the pharmacy is state-licensed with USP standards and COA testing
Red Flags: What to Avoid With Compounded Tirzepatide
Not all compounded tirzepatide is created equal. The FDA and major medical organizations have flagged several concerning practices in the compounding market:
Warning Signs of a Problematic Compounding Pharmacy
- No prescription required: Compounded tirzepatide always requires a valid prescription from a licensed physician.
- No Certificate of Analysis (COA): Legitimate pharmacies test each batch and can provide a COA confirming purity and potency.
- Unusually low prices (under $100/month): Prices that seem too good to be true may indicate substandard ingredients or unregulated sources.
- No state pharmacy license verifiable: Every compounding pharmacy must be licensed in the state it ships to. Verify via your state board of pharmacy.
- Unapproved added ingredients: Some operations add unauthorized substances (e.g., B12, NAD+) without clinical evidence for co-formulation safety.
Trimi partners only with pharmacies that meet USP 797 sterile compounding standards, are state-licensed, and provide full COA documentation. For more on safe access to compounded GLP-1 medications, see our Ozempic vs Mounjaro comparison.
How Trimi Provides Access to Tirzepatide
Trimi is a telehealth platform that connects eligible patients with licensed physicians who can prescribe compounded tirzepatide at significantly lower cost than brand-name alternatives. The process starts with a comprehensive online medical assessment reviewed by a US-licensed physician within 24–72 hours.
If you qualify, your prescription is sent to a state-licensed 503A or 503B compounding pharmacy, and your medication is shipped directly to your home. Trimi's clinical team provides ongoing dosing support, side effect management, and regular check-ins throughout your treatment journey.
To understand how compounded tirzepatide fits into the broader GLP-1 landscape, read our comprehensive tirzepatide vs semaglutide 2026 comparison.
Frequently Asked Questions
Is tirzepatide the same as Mounjaro?
Yes and no. Tirzepatide is the active ingredient — the actual drug molecule. Mounjaro is a brand name for tirzepatide manufactured by Eli Lilly and FDA-approved specifically for type 2 diabetes management. So every Mounjaro injection contains tirzepatide, but not all tirzepatide formulations are Mounjaro. Zepbound is another brand name for the same molecule, approved for obesity.
What is the difference between Mounjaro and Zepbound?
Both Mounjaro and Zepbound contain identical tirzepatide at the same doses (2.5 mg through 15 mg). The only differences are the FDA approval indication, the pen color/labeling, and in some cases the price. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management (BMI 30+, or BMI 27+ with a weight-related condition). Clinically, they are interchangeable for patients who qualify for both.
How much does Mounjaro cost per month?
Brand-name Mounjaro retails at approximately $1,023–$1,069 per month without insurance. With commercial insurance that covers it for type 2 diabetes, out-of-pocket costs may be $25–$150/month. Eli Lilly offers a savings card (Mounjaro Savings Card) for eligible commercially insured patients. However, many patients — particularly those seeking it for weight loss only — do not have insurance coverage.
Is compounded tirzepatide legal?
As of April 2026, compounded tirzepatide remains available through 503A and 503B pharmacies for individual patients. Unlike semaglutide, tirzepatide has not been removed from the FDA drug shortage list as of early 2026. This means FDA shortage-based compounding exemptions still apply. However, the regulatory environment is evolving and patients should verify current status with their provider.
Is compounded tirzepatide as effective as Mounjaro?
Compounded tirzepatide contains the same active ingredient (tirzepatide base) as Mounjaro. When compounded by a legitimate, state-licensed 503A or 503B pharmacy using pharmaceutical-grade tirzepatide, the active molecule is identical. Differences may exist in inactive ingredients, preservatives, or formulation. There are no head-to-head clinical trials, but mechanistically the efficacy should be equivalent at the same dose.
Who should use compounded tirzepatide instead of Mounjaro?
Compounded tirzepatide is most appropriate for patients who: (1) do not have insurance coverage for Mounjaro or Zepbound, (2) cannot afford the $1,000+/month brand cost, (3) do not have type 2 diabetes (limiting Mounjaro access), or (4) have been denied prior authorization. If you have full insurance coverage and Mounjaro is affordable, the brand-name version offers the most regulatory certainty.
What doses does tirzepatide come in?
Both Mounjaro and Zepbound come in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all as once-weekly subcutaneous injections. The standard titration starts at 2.5 mg for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated. Maximum approved dose is 15 mg weekly. Compounded tirzepatide is available in the same dose range from most pharmacies.
Sources & References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1)
- Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503–515. (SURPASS-2)
- U.S. Food and Drug Administration. "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes." FDA Press Release. May 13, 2022.
- U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA Press Release. November 8, 2023.
- Eli Lilly and Company. "Mounjaro (tirzepatide) Full Prescribing Information." 2023.
- American Society of Health-System Pharmacists. "Drug Shortages: Tirzepatide." Updated 2026.